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Techniques for diagnosing osteoporosis: A systematic review of cost-
effectiveness studies 
 
Abstract 
Objectives. The study question was whether dual-energy X-ray absorptiometry (DXA) alone is more cost-
effective for identifying postmenopausal women with osteoporosis than a two-step procedure with 
quantitative ultrasound sonography (QUS) plus DXA. To answer this question, a systematic review was 
performed.  
Methods. Electronic databases (PubMed, INAHTA, Health Evidence Network, NIHR, the Health 
Technology Assessment programme, the NHS Economic Evaluation Database, Research Papers in 
Economics, Web of Science, Scopus, and EconLit) were searched for cost-effectiveness publications. Two 
independent reviewers selected eligible publications based on the inclusion/exclusion criteria. Quality 
assessment of economic evaluations was undertaken using the Drummond checklist. 
Results. Seven journal articles and four reports were reviewed. The cost per true positive case diagnosed by 
DXA was found to be higher than that for diagnosis by QUS+DXA in 2 articles. In one article it was found 
to be lower.  In three studies the results were not conclusive. These articles were characterised by the 
differences in the types of devices, parameters and thresholds on the QUS and DXA tests and the unit costs 
of the DXA and QUS tests as well as by variability in the sensitivity and specificity of the techniques and the 
prevalence of osteoporosis. 
Conclusions. The publications reviewed did not provide clear-cut evidence for drawing conclusions about 
which screening test may be more cost-effective for identifying postmenopausal women with osteoporosis.  
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Introduction 
Osteoporosis has become an increasingly recognised health concern by the medical community and 
the public. The hallmark of this skeletal disorder is diminished bone strength predisposing to a 
higher risk of fracture (1). Two types of osteoporosis are distinguished: 
- primary osteoporosis, attributable to aging, menopause, and lifestyle-related factors, such as 
smoking, alcohol, diet and physical inactivity; 
- secondary osteoporosis, caused by diseases and/or the use of drugs. 
Primary osteoporosis affects millions of postmenopausal women and a growing number of men. 
Because of induced hormonal changes, it is more common among women after menopause. As 
such, it is perhaps the widest ranging social, physical and economic impact of oestrogen deficiency 
(2-4) and a leading risk factor for bone fractures in menopausal women (5). The incidence of 
osteoporotic fractures in Western countries is rising as the life expectancy lengthens. There is a 
clear relationship between bone mineral density (BMD) and fracture risk that facilitates the use of 
BMD as a predictive factor for the development of osteoporotic fractures. This approach, however, 
has two drawbacks: its predictive value is rather low in general (6), and its sensitivity further 
decreases with patients’ increasing risk and age. 
To achieve a higher sensitivity that is not affected by age, additional clinical risk factors 
independent of BMD, e.g., prevalent rheumatoid arthritis, smoking or excessive alcohol 
consumption, have been added to the evaluation. 
Through this evaluation, an algorithm was developed that predicts the absolute 10-year fracture risk 
with a much higher predictive value than that from the evaluation of BMD or clinical risk factors 
alone (7,8). 
The algorithm is known as FRAX® and is available free of charge at www.shef.ac.uk/FRAX®/. 
After the FRAX® algorithm is calibrated to local hip fracture and death rates, it is applicable to any 
geographic region (9). 
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According to a World Health Organisation (WHO) study group (10), the gold standard test for 
osteoporosis screening is the measurement of bone mineral density (BMD) by dual-energy X-ray 
absorptiometry (DXA or DEXA). Developed roughly 20 years ago (11), DXA is the method of 
choice for diagnosing osteoporosis and, consequently, fracture risk estimation.  
Recently, there has been increased interest in the use of quantitative ultrasound sonography (QUS) 
(12,13) . 
However, employing QUS to diagnose osteoporosis is somewhat problematic. The reason for this is 
that the WHO diagnostic classification applied to DXA T-scores cannot be used for QUS because 
QUS T-scores are not equivalent to T-scores derived by DXA (14); the explanation for this finding 
is that the two techniques measure distinct bone properties. Approaches to overcoming this dilemma 
require appropriate conversion equations and predefined, device-specific diagnostic thresholds; 
these, however, are still in development. Although osteoporosis screening by QUS is not 
recommended as a substitute for DXA, it may offer some potential advantages as a pre-test: QUS is 
easy to use, radiation free, and requires no special facilities for operation. For these reasons, QUS 
has been proposed as a pre-screening tool, with DXA offered only to those women identified by 
QUS as being at high risk for having osteoporosis (12,15,16). Consistent with the review of 
Schousboe (17) and the study by Nayak (18), consensus is lacking about the DXA test or the 
sequence QUS+DXA, the threshold for selecting individuals for treatment and the optimal age at 
which to initiate screening (17,18). 
The policy question we posed for this study was whether DXA alone was more cost-effective for 
identifying postmenopausal women with osteoporosis than was a two-step procedure combining 
QUS with DXA. To answer this question, we performed a systematic review of the literature and 
evaluated the currently available evidence according to the PRISMA criteria (19). 
This study is part of a research series in health technology assessment developed by the Department 
of Public Health and San Giovanni Battista University Hospital (Turin Italy). The research series 
focused on the performance and economic evaluations of different techniques (20,21).
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Materials and Methods 
Methods 
 
Search strategy 
In 2012, two researchers independently performed systematic searches of international databases to 
identify publications from PubMed, the International Network of Agencies for Health Technology 
Assessment [INAHTA], the Health Evidence Network [HEN], the National Institute for Health 
Research [NIHR] Health Technology Assessment programme, the National Health Service [NHS] 
Economic Evaluation Database, Research Papers in Economics [RePEc], the Web of Science, 
Scopus, and EconLit using MESH terms, text words and acronyms in multiple combinations. 
All papers written in English, French and Italian, regardless of their dates of publication, were 
considered for our purposes.  
Details of the search procedure are available in Supplementary Table 1. 
 
Selection strategy and criteria 
In the first stage, the researchers analysed the search results individually to find potentially eligible 
publications. The publications were sorted by title and abstracts; all irrelevant studies (lack of 
pertinence, identical publications found on more than one database) and reviews were excluded. 
In the second phase, only the studies that met the following inclusion criteria were selected:  
− the patients had to be postmenopausal women; 
− the study had to compare QUS plus DXA with DXA alone. No exclusion criterion 
was applied to the publication types; 
− the measurement of effectiveness had to be reported as the number of osteoporotic 
subjects accurately diagnosed, that is, the number of true positive cases; 
− the publications had to contain sensitivity and specificity or allow for their 
calculation; 
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−  the technique used had to be DXA at the femoral neck or lumbar spine or total hip  
(22) and calcaneal QUS;  
− the economic evaluation of resources required to provide the alternative techniques 
(DXA and QUS test costs) had to be included. 
The exclusion process was performed by two independent reviewers. Discrepancies were resolved 
through the intervention of another reviewer. 
 
Quality assessment  
The 10-item Drummond checklist was used to assess the methodological quality of the included 
studies (23). Details of the quality assessment are available in Supplementary Table 2. The 
Drummond checklist provides a global assessment of the quality of evidence, but it did not form the 
basis for accepting or rejecting articles. 
 
Data Extraction  
The researchers reviewed the selected full texts for eligibility and extracted the required data. For 
each publication, the following information was retrieved: 
- Study characteristics: Publication year, Country and setting, Sample size, Prevalence of 
osteoporosis, Recruitment design, Prospective economic evaluation; 
-  Technique characteristics: Types of devices; Sites of application;  
- Screening strategies with DXA and QUS, specifying QUS parameters and thresholds for women 
who required a DXA measurement for accurate diagnosis; 
- Economic evaluation characteristics: Types of costs, Currencies and financial years; Cost 
breakdowns (i.e., the systematic process of identifying the individual elements that composed 
the unit costs of the QUS and DXA tests); 
-  DXA and QUS test results: Number of osteoporotic subjects accurately diagnosed (true 
positives); QUS sensitivity and specificity when available.  
6 
 
 
Economic analysis 
Our review was conducted to analyse the cost per true positive case of two different strategies for 
osteoporosis screening and their incremental cost-effectiveness. 
Cost per true positive case was calculated as total cost divided by number of true positive cases 
detected with the two different approaches: (1) the total cost per osteoporotic subject based on DXA 
measurement alone, i.e., without a QUS screen and (2) the total cost per osteoporotic subject 
identified by QUS+DXA, i.e., using QUS as a screen. This cost was the sum of the total cost of 
performing the QUS test in all subjects and the cost of performing additional DXA testing in those 
women who were positively detected with QUS.  
For DXA, osteoporosis is defined by the WHO as a BMD that is 2.5 standard deviations or more 
below the mean peak bone mass in healthy young adults (a T-score ≤ -2,5) (24). 
Incremental cost-effectiveness was calculated as the extra cost needed to generate each additional 
true positive result. 
To compare the costs per true positive case, the current costs of the DXA and QUS tests were 
adjusted to Euro currency and inflation (base year 2006, i.e., the last year in the published studies 
used to estimate the test costs) (25,26) and exchange rates (27). 
Cut-off values were calculated that indicated the level below which, based on the ratio unit cost of 
the QUS test and the unit cost of the DXA test, a true positive case diagnosed by the QUS+DXA 
technique was more cost-effective than was a true positive case detected by DXA alone. 
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Results 
 
Overall, 136 publications were found. After the titles and abstracts were read, 85 publications were 
excluded as irrelevant (lack of pertinence or duplicates) or as reviews. 
Of the remaining 51 publications, 40 were excluded because they did not meet the inclusion criteria.  
Finally, a total of 11 publications, 7 journal articles and 4 reports were included in our review (Fig. 
1). The four reports provided the basis for the discussion. 
The quality of the journal articles was good. Each article fulfilled six to ten items on the Drummond 
checklist (Supplementary Table 2).  
The characteristics of the studies are illustrated in Table 1.  
All journal articles were cohort studies, and their analyses were performed from the perspective of 
the third-party payer. The women’s ages ranged from 40 to 70. The prevalence of osteoporosis 
ranged between 7.85% and 57.70%. 
Three studies used mcCue CUBA Clinical (Mc Cue Plc, Winchester, UK), two used Wolkers Sonix 
UBA575 (Walker Sonics Inc. Worcester, MA) and one used the Sahara Clinical Bone Sonometer 
(Hologic Inc., Bedford, MA) for QUS test (Table 1). Three studies measured the broadband 
ultrasound attenuation (BUA) of the right calcaneus, two of the left calcaneus and two of both 
calcanea. 
In terms of strategy, five studies adopted one QUS threshold value, and two studies used different 
QUS threshold values to identify women who needed a DXA measurement for an accurate 
diagnosis. 
Five studies used BUA measurements as the QUS parameter and two used T-scores (Table 1).  
Five studies reported the real cost of the DXA and QUS tests; two studies reported the charges or 
estimated costs (Table 1). Two of the 7 studies gave a breakdown of different cost items (Table 1).  
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All studies reported that the DXA test was costlier than the QUS test, with some stating that the cost 
of the DXA test was nine-fold or eight-fold higher (28-31) and others reporting that it was two-fold 
(32), three-fold (31,32), four-fold (33) or five-fold higher (34) (Table 2).  
According to Langton (28,29) and Marin (30), the cost per true positive case diagnosed by DXA 
was higher than that for diagnosis by QUS+DXA. Kraemer (33), however, estimated that the cost 
per osteoporotic subject identified by DXA alone was less than the cost per osteoporotic subject 
identified by QUS+DXA. In contrast, three studies (31,32,34) reported that the cost per osteoporotic 
subject identified by DXA alone was higher or lower than that of QUS+DXA (Figure 2).  
For all of the studies, a cut-off value was calculated that indicated under what ratio unit cost for the 
QUS and DXA tests a case diagnosed by combining QUS+DXA was more cost-effective than was a 
case diagnosed by DXA alone. Depending on the study, cases diagnosed by QUS+DXA were cost-
effective as long as the cost of the QUS test was between 7% and 41% of the cost of the DXA test 
(for each study, the cut-off values were as follows: 41% in the studies by Langton, 30% in Sim 
2000 and 36% in Sim 2005, 14% in Marin, 7–22% in Kraemer, and 13–32% in Hiligsmann) (Table 
2). 
The incremental cost to diagnose one more case ranged approximately between 30 and 2,000 Euros 
(Table 2). 
In three cases, there were incremental savings associated with diagnosing each additional case: 
QUS 80 Db/MHz and QUS 85 Db/MHz, in Kraemer (33) with a QUS T-score = 0 in Hiligsmann 
(34) (Table 2).  
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Discussion 
The policy question we posed for this study was whether DXA alone was more cost-effective for 
identifying postmenopausal women with osteoporosis than was a two-step procedure using QUS 
plus DXA. In a previous review in 2008, Schousboe (35) concluded that on balance, the cost-
effectiveness studies of heel ultrasounds did not make a convincing case that heel ultrasounds 
should be employed in places where central DXA was available. In his review, Schousboe did not 
compare cost per true positive case detected by DXA alone with cost for QUS+DXA; he did not 
analyse variables such as, e.g., sensitivity and specificity or type of costs. In contrast, in our review, 
we made a comparison and took into account a number of variables. 
In any event, the results of our review did not allow for definitive conclusions about the better 
technique for diagnosing osteoporosis, most likely because of the lack of homogeneity among the 
studies. One of the difficulties we encountered in comparing the studies was the different QUS 
devices used. They differ substantially with respect to the  algorithms they used, the parameters 
they measured, and the strength of the empirical evidence supporting their use, among other aspects 
(36,37). Another difficulty we encountered in comparing the studies was the different ways the 
QUS parameter was measured: BUA with different Db/MHz values or a QUS T-score (0.0, -.05, -
1.0, -1.5, -2.0, -2.5). According to the INAHTA report (37), these parameter measurements are not 
directly comparable.  
In addition, there are different sites for the device applications. Only Sim (31, 32) measured the 
BUA of the right and left calcanea and showed that QUS sensitivity increased with the use of the 
left calcaneus in comparison with that of the right calcaneus.  
Furthermore, there were differences concerning the costs for true positive cases.  
Our review shows the inhomogeneous results likely caused by (i) the types of costs used to 
determine the values of the QUS and DXA tests, (ii) the items included in the evaluations of the 
DXA and QUS test costs, (iii) the different sensitivities and specificities of the QUS tests and (iv) 
the ages of the screened populations and their prevalence of osteoporosis.  
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Indeed and about point:  
(i) Kraemer (33) found the cost per QUS test and DXA test to be higher than did any other study, 
perhaps because he used Medicare reimbursement rates rather than real costs; (ii) the costs of the 
DXA test in Sim 2005 (32) consisted of staff salaries (technologist, doctors, nurse, clerk, training 
and development), equipment (depreciation over 7 years, maintenance, consumables interest) and 
assumed overhead of 20% or more. In Marin (30), costs consisted of salaries for the technician and 
the doctors, equipment and maintenance and assumed overhead of 10%. The different resources 
identified, enumerated and valued determined that the DXA test in Sim 2005 (32) was more 
expensive than that used in Marin (30); (iii) in Hiligsmann (34), the cost per true positive case 
detected by QUS+DXA was higher than the cost for diagnosis by DXA alone when the QUS T-
score = -2.5 or = 0.0. In the other situations, true positive cases diagnosed by QUS+DXA were less 
expensive than were those identified by DXA alone. This could be explained by the range in the 
QUS sensitivity and specificity, between 33% and 93% and between 24% and 93%, respectively, so 
that the cost per true positive case diagnosed by QUS+DXA was higher when there were many 
false positives or there was low QUS sensitivity; (iv) a significant factor in the cost per true positive 
case is the prevalence of osteoporosis at the different ages. Langton 1999 (29) showed that for 
women aged 50–55, the prevalence of osteoporosis was only 7.85%, whereas Langton 1997 (28) 
found that the prevalence for women aged 60–69 was 24.3%. As the prevalence of osteoporosis 
within a population increases, the total screening cost is divided over a large number of osteoporotic 
subjects and the cost per subject identified decreases. Hence, the cost per true positive case 
diagnosed by DXA in Langton 1999 (29) was 967.83 Euros for the 50–54 year cohort, falling to 
312.52 Euros for the 60–69 year cohort in Langton 1997 (28). 
Most of the authors suggested an extra cost needed to generate each additional true positive result 
using DXA compared with QUS+DXA because of the higher DXA test unit cost and the low QUS 
sensitivity. These results confirmed Nayak’s (18) conclusions. Nayak demonstrated that different 
osteoporosis screening methods were effective and that there were incremental costs for DXA 
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screening per additional identified case. In contrast, Kraemer (33) suggested cost savings per 
additional true case of osteoporosis diagnosed by DXA when the QUS parameter was 80 and 85 
Db/MHz and the sensitivity was 91% and 95% for QUS respectively, similar to Hiligsmann (34), 
with a QUS T-score=0 and a sensitivity of 93%.  
In conclusion, our review aimed to assess the available evidence on the cost-effectiveness of 
different techniques for diagnosing osteoporosis in postmenopausal women. 
Although there is some evidence that screening is effective in identifying postmenopausal women 
with osteoporosis, our results suggest that the role of QUS in the diagnosis of osteoporosis remains 
unclear (39,40) and show that from the perspective of the third-party payer, QUS may be useful as a 
pre-screening tool for osteoporosis if the cost ratio between QUS test and DXA test unit costs is 
below a specified cut-off value (expressed in %) and if the QUS sensitivity and specificity are high.  
To arrive at a definitive conclusion of whether DXA alone is more cost-effective for identifying 
postmenopausal women with osteoporosis than is a two-step procedure with QUS plus DXA and is 
in line with the INAHTA report (41), our results underscored that homogenous cost-effectiveness 
studies are needed to elucidate the question as to which technique is less costly and more effective 
in the identification of patients with osteoporosis. In this way, some of the studies’ biases could be 
overtaken, e.g., conclusions cannot be extended to women younger or older than the target group 
being examined; costs and resource use that were not adequately reported. The problem is relevant 
because the experts agreed that in the future, fracture prediction will change with the use of the 
more complex FRAX® system, which integrates both DXA and QUS+DXA data. 
In addition, the problem is significant because the evidence for which is the most cost-effective—
DXA only or QUS + DXA—is important for policy makers, who have then to combine these results 
with other information about possible interventions for treating osteoporosis and actual health 
outcomes, such as osteoporosis-related fracture reduction. 
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In fact, because there is evidence that fractures and their complications are the relevant clinical 
sequelae of osteoporosis; that osteoporosis-related fractures create a heavy economic burden; and 
that patients with osteoporosis reduced their fracture risk with pharmacotherapy, a comprehensive 
approach to diagnosing and managing osteoporosis is recommended to decision makers. This 
approach should take into account the cost of the screening programme but also the cost of the 
resources necessary to treat true positive cases and the benefits of these resources to health 
outcomes. 
In addition to being homogeneous, studies on cost-effectiveness must be conducted with greater 
methodological rigor because health care decision makers need to be sure that the evidence on 
efficiency is reliable and can be applied to their own situations. 
In this review, the process of critically appraising health economic evaluation studies assisted by 
Drummond checklists showed that the quality of published health economic evaluations varies. 
Some studies did not provide sufficient evidence for decision makers in the countries in which they 
were conducted: e.g., Langton (28,29) in the UK and Kramer (33) in the United States did not 
provide details of the costs of the two tests and did not justify the types of costs used, and  
Hiligsmann (34) in Belgium did not employ a sensitivity analysis. Thus, decision makers cannot 
judge if the findings are applicable to their health service or social insurance.  
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Figure legends 
 
Figure 1. Study Flow Diagram – steps for selecting the studies for inclusion in this review. 
 
Figure 2. Cost per true positive case with DXA* and QUS+DXA** in 2006 Euros.  
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Table 1. The characteristics of the studies 
 
Study and 
publication 
year 
Country 
(Setting) 
Sample 
size 
Recruitment 
design 
 
Prevalence 
of 
osteoporosis 
Perspective 
of 
economic 
evaluation 
Type of device 
Site of 
application 
Strategies  
 
Types of 
costs, 
currency 
and 
financial 
year 
Cost 
breakdown 
Langton 
(1997) [28] 
UK (Centre 
for Metabolic 
Bone 
Disease, 
Hull) 
107 
women 
aged 60–
69, mean 
age, 
64.2±2.8  
NA 24.30% 
National 
Health 
Services in 
UK 
DXA (pencil-
beam Lunar 
DPX-L); 
QUS (CUBA 
clinical II 
scanner, McCue 
Ultrasonic, 
Winchester, 
UK) 
Right 
femoral 
neck or 
lumbar 
spine for 
DXA; 
Left 
calcaneus 
for QUS 
 
1 DXA 
for all  
2. QUS 
for all and 
DXA for 
those with 
BUA 
score 
QUS =60 
Db/MHz 
Real cost*, 
£, 
1997 
No 
Langton 
(1999) [29] 
UK (Centre 
for Metabolic 
Bone disease, 
599 
women 
aged 50–
Cohort of 
women was 
provided from 
7.85% 
National 
Health 
Services in 
DXA (pencil-
beam Lunar 
DPX-L); 
Right 
femoral 
neck or 
1 DXA 
for all  
2. QUS 
Real cost*, 
£, 
1997 
No 
18 
 
Hull) 54, mean 
age, 
52.18±1.35 
the data set of 
a different 
study  
UK QUS (Walker 
Sonix UBA575) 
lumbar 
spine for 
DXA; 
Right 
calcaneus 
for QUS 
for all and 
DXA for 
those with 
BUA 
score 
QUS =75 
Db/MHz 
Sim (2000) 
[31] 
UK (Cardiff 
Royal 
Infirmary) 
46 women 
aged 50–
80, mean 
age 69 
Cohort of 
consecutive 
women who 
presented at 
the Accident 
and 
Emergency 
Department at 
the Cardiff 
Royal 
Infirmary 
58.70% 
National 
Health 
Services in 
UK 
DXA (Hologic 
QRD 1000W, 
Hologic Inc., 
Waltham, MA, 
USA); 
QUS (CUBA 
clinical II 
scanner, McCue 
Ultrasonic, 
Winchester, 
UK) 
Total hip or 
lumbar 
spine for 
DXA; 
Left 
calcaneus 
for QUS 
 
1 DXA 
for all  
2. QUS 
for all and 
DXA for 
those with 
BUA 
score 
QUS =60 
Db/MHz 
Real cost* 
Estimated 
cost**, £, 
1997 
No 
Marin 
(2004) [30] 
Spain (Three 
primary care 
centres in 
metropolitan 
267 
women 
aged ≥ 65, 
mean age 
Cohort of 
women 
without 
neoplastic or 
55.81% 
National 
Health 
Services in 
Spain, 
DXA (Hologic 
QRD 
4500SLTM, 
Hologic Inc., 
Femoral 
neck for 
DXA; 
Heel for 
1 DXA 
for all  
2. QUS 
for all and 
Real cost*, 
€, 
2001 
 
Yes 
19 
 
Barcelona) 
 
72.3±5.3 metabolic 
bone disease 
who were 
attended to for 
any medical 
reason in 
three primary 
care centres 
(non-
probabilistic 
sampling of 
consecutive 
cases) 
 Waltham, MA, 
USA), 
QUS (Sahara 
Clinical Bone 
Sonometer, 
Hologic Inc., 
Bedford). 
QUS 
 
 
DXA for 
those with 
BMD 
QUS T-
score <0.5 
to >-2.5 
Sim (2005) 
[32] 
UK (Cardiff 
open access 
bone 
densitometry 
service) 
115 
women 
aged 40–
80, mean 
age 69 
All consenting 
women 
referred by 
their GPs via 
the Cardiff 
open access 
bone 
densitometry 
service 
46.09% 
National 
Health 
Services in 
UK 
DXA (Hologic 
QRD 1000W, 
Hologic Inc., 
Waltham, MA, 
USA); 
QUS (CUBA 
clinical II 
scanner, McCue 
Ultrasonic, 
Total hip or 
lumbar 
spine for 
DXA; 
Right 
calcaneus 
for QUS 
 
1 DXA 
for all  
2. QUS 
for all and 
DXA for 
those with 
BUA 
score 
QUS =60 
Real cost*, 
£, 
2002 
Yes 
20 
 
Winchester, 
UK) 
Db/MHz 
Kramer 
(2006) [33] 
USA (NA) 
5993 
women 
aged ≥ 70 
Only women 
with both 
DXA 
and QUS 
measurements 
within Study 
of 
Osteoporotic 
Fractures 
(SOF) cohort 
28.10% Medicare  
DXA (QDR 
1000 
instrument, 
Hologic, 
Bedford, 
Mass.), 
QUS (UBA 575 
instrument 
Walker-Sonix, 
Worcester, 
Mass.). 
Femoral 
neck for 
DXA; 
Calcaneus 
for QUS 
 
1 DXA 
for all  
2. QUS 
for all and 
DXA for 
those with 
BUA 
score 
QUS =50; 
55; 60; 
65; 70; 
75; 80 e 
85 
Db/MHz 
Charge, $,  
2000 
No 
Hiligsmann 
(2008) [34] 
Belgium 
(NA) 
1000 
women 
aged 50-80 
No 
recruitment 
but 
hypothetical 
cohort 
19.93% 
Social 
Insurance  
NA 
NA for 
DXA; 
Calcaneus 
for QUS 
1 DXA 
for all  
2. QUS 
for all and 
DXA for 
those with 
Cost 
estimated**, 
€, 
2006 
No 
21 
 
BMD 
QUS T-
score 
=0;=-
0.5;=-1; 
=-1.5; =-
2;≤ -2.5 
*Cost estimated= when resources that required alternative methods (QUS and DXA) were proposed by institutions or the literature.  
**Real cost= when actual resources that required alternative methods (QUS and DXA) were identified, enumerated and valued. 
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Table 2. Sensitivity, Specificity, Unit cost of the  QUS test and DXA test, incremental cost and cut-off value (2006 euros)  
 
Study and 
publication year 
Parameter and  
Thresholds in 
QUS for 
osteoporosis 
Unit cost 
DXA test 
(euros) 
Unit cost 
QUS test 
(euros) 
QUS 
sensitivity  
QUS 
specificity  
Incremental 
cost-effectiveness 
of DXA alone vs 
QUS+DXA 
(euros) 1 
Cut-off value2 
Langton (1997) 
[28] 
BUA score QUS 
=60 Db/MHz 75.94 a 8.18 a 73% 81% 666.84 <41% 
Langton (1999) 
[29] 
BUA score QUS 
=75 Db/MHz 75.94 a 8.18 a 73% 73% 2052.96 <41% 
Sim (2000) [31] BUA score QUS 
= 60 Db/MHz 
75.94 a 25.31 ab 93% 84% 101.25 <30% 
75.94 a 8.18 b 93% 84% 495.21 <29% 
Marin (2004) 
[30] 
BMD QUS T-
score ≤ -2.5 14.77 b 1.84 b 97% 94% 126.51 <14% 
Sim (2005) [32] BUA score QUS 
= 60 Db/MHz 
50.47 c * 25.99 c 81% 89% 29.20 <36% 
69.59 c** 25.99 c 81% 89% 153.46 <36% 
Kramer (2006) 
[33] 
BUA score QUS 
50 Db/MHz 128.78 d 32.92 d 34% e 90% e 400.35 <22% 
BUA score QUS 128.78 d 32.92 d 47% e 82% e 417.97 <17% 
23 
 
55 Db/MHz 
BUA score QUS 
60 Db/MHz 128.78 de 32.92 d 60% e 71% e 423.21 <20% 
BUA score QUS 
S 65 Db/MHz 128.78 d 32.92 d 71% e 59%e 396.32 <21% 
BUA score QUS 
70 Db/MHz 128.78 d 32.92 d 79% e 47% e 304.18 <10% 
BUA score QUS 
75 Db/MHz 128.78 d 32.92d 86% f 35%e 106.28 <18% 
BUA score QUS 
80 Db/MHz 128.78 d 32.92 d 91% e 24%e -314.64 <7% 
BUA score QUS 
85 Db/MHz 128.78 d 32.92 d 95% e 16% e -1070.04 <15% 
Hiligsmann 
(2008) [34] 
BMD QUS T-
score ≤ -2.5 47.00 10.00 33% 93% 234.52 <19% 
BMD QUS T-
score = -2 47.00 10.00 49% 86% 266.90 <28 
BMD QUS T-
score =-1.5 47.00 10.00 66% 74% 312.25 <32% 
BMD QUS T-
score =-1 47.00 10.00 79% 58% 330.88 <28% 
BMD QUS T- 47.00 10.00 88% 39% 248.39 <21% 
24 
 
score = -0,5 
BMD QUS T-
score =-0 47.00 10.00 93% 24% -23.70 <13% 
1 Incremental cost –effectiveness is calculated as the extra cost needed to generated each additional true positive result  
2 A cut-off value was calculated and  indicated under what ratio unit cost for the QUS and DXA tests a case diagnosed by combining QUS+DXA was more cost-effective than 
was a case diagnosed by DXA alone 
a The values in € 2006 are obtained adjusting for an inflation rate of 1.1332 and for an exchange rate £/€ of 1.,4892  
b The values in € 2006 are obtained adjusting for an inflation rate of 1.1095  
c The values in € 2006 are obtained adjusting for an inflation rate of 1.1035 and for an exchange rate £/€ of 1.4892 
d The values in € 2006 are obtained adjusting for an inflation rate of 1.1710 and for an exchange rate $/€ of 0.,8268 
e Our own calculations 
* DXA fan beam  
** DXA pencil beam 
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Supplementary Table 1. Search strategies in 2012 
 
Database Search strings 
Pubmed ("Bone Density"[Mesh] OR "Bone and Bones"[Mesh]) 
AND ("Quantitative ultrasonometry" OR "Quantitative 
ultrasound" OR QUS) AND ("Dual-energy X-ray 
absorptiometry" OR DXA OR DEXA) AND (econom* OR 
cost* OR "Economics"[Mesh]) 
 
Pubmed ("Quantitative ultrasonometry" OR "Quantitative 
ultrasound" OR QUS) AND ("Dual-energy X-ray 
absorptiometry" OR DXA OR DEXA) AND (econom* OR 
cost* OR "Economics"[Mesh]) 
 
 
International Network of Agencies for Health 
Technology Assessment INAHTA 
Health Evidence Network (HEN) 
National Institute for Health Research (NIHR) Health 
Technology Assessment programme 
National Health Service (NHS) Economic Evaluation 
Database 
Research Papers in Economics (RePEc) 
QUS AND DXA OR DEXA 
 
 
WEB OF SCIENCE 
SCOPUS* 
Topic=(qus) AND Topic=(dxa) AND Topic=(econom*) 
 
*SCOPUS was searched with a different strategy from that used for Pubmed, which allowed for more detailed and 
sophisticated searches. 
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Supplementary Table 2. Quality assessment with the 10-item Drummond checklist  
Check list 
1.Was a well-defined question posed in an answerable form?  
2.Was a comprehensive description of the competing alternatives given (i.e., could you tell who 
did what to whom, where, and how often)?  
3.Was the effectiveness of the programme or services established?  
4.Were all of the important and relevant costs and consequences for each alternative identified?  
5.Were the costs and consequences measured accurately in appropriate physical units (e.g., hours 
of nursing time, number of physician visits, lost work days, gained life years)?  
6.Were the cost and consequences valued credibly? 
7.Were the costs and consequences adjusted for differential timing?  
 
8.Was an incremental analysis of the costs and consequences of alternatives performed?  
 
9.Was allowance made for uncertainty in the estimates of the costs and consequences?  
 
10.Did the presentation and discussion of the study results include all issues of concern to the 
users?  
 
Study and 
publication 
year 1 2 3 4 5 6 7 8 9 10 
Langton 
(1997) [28] √ √ √ √ 0 0 √ 0 0 √ 
Langton 
(1999) [29] √ √ √ √ 0 0 √ 0 0 √ 
Sim (2000) 
[31] √ √ √ √ 0 0 √ 0 √ √ 
Marin 
(2004) [30] √ √ √ √ √ √ √ √ √ √ 
Sim (2005) 
[32] √ √ √ √ 0 √ √ 0 0 √ 
Kramer 
(2006) [33] √ √ √ √ 0 0 √ 0 √ √ 
Hiligsmann 
(2008) [34] √ √ √ √ 0 0 √ √ 0 √ 
Yes =√ ; Νο=0  
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Figure 1. Study Flow Diagram – steps of a selection of studies for inclusion in this review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Search Results combined (n=136)
PubMed (n= 53)
INAHTA (n=8)
NHS Economic Evaluation Database (n. 10)
ISIWeb of Science (n=5)
Scopus (n=60)
EconLit (n=0)
HEN (n=0) 
NIHR (n=0)
RePEc (n=0)
Publications screened on the basis of the title and abstract
Excluded (n=85 )
PubMed (11): 10 for lack of pertinence; 1 was a review
INAHATA (6): 6 for lack of pertinance
NHS Economic Evaluation Database (5): 4 were duplicated; 1 was a review
ISIWeb of Science (4): 4 were duplicated
Scopus (59): 48 for lack of pertinence; 11 were duplicated
Publications eligible for inclusion (n=51 )
Excluded due to no inclusion criteria (n= 40) 
PubMed (n=36): 32 did not give an economic evaluation of resources required to provide
the alternative techniques; 2 were not comparative studies; 2 did not give a measurement of 
effectiveness.
NHS Economic Evaluation Database (2) : 2 did not give an economic evaluation of 
resources required to provide the alternative techniques
ISIWeb of Science (n=1): 1 did not give an economic evaluation of resources required to 
provide the alternative techniques
Scopus (n=1): 1 did not give an economic evaluation of resources required to provide the 
alternative techniques
Publications included (n=11) 
PubMed (Journal articles=6)
INAHATA (Reports=2)
NHS Economic Evaluation Database (Reports =2; Journal 
articles=1)
Literature Search: PubMed, INAHTA, NHS Economic Evaluation
Database, ISIWeb of Science, Scopus, HEN, NIHR, EconLit, RePEc
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Figure 2. Cost per true positive case with DXA* and QUS+DXA** in 2006 euros.  
 
*Cost per true positive case was calculated as the total cost divided by the number of true positive cases detected with DXA  
**Cost per true positive case was calculated as the total cost divided by the number of true positive cases detected with QUS+DXA. The total cost is the sum of the total cost of 
performing the QUS test on all subjects and the cost of performing additional DXA on those women who were positively detected with QUS.  
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